Phase 3: Rapid Relief in Thyroid Eye Disease With Veligrotug
Veligrotug, a monoclonal antibody, has shown promising results in treating moderate-to-severe thyroid eye disease. In a phase 3 trial, patients experienced significant improvements in proptosis and diplopia after receiving the treatment. The study indicates that veligrotug may offer a new therapeutic option for managing this condition.
- ▪Veligrotug was administered as five intravenous infusions over 12 weeks to patients with moderate-to-severe active thyroid eye disease.
- ▪At week 15, 70% of patients treated with veligrotug showed a reduction in proptosis compared to only 5% in the placebo group.
- ▪The treatment was generally well tolerated, with a low discontinuation rate and no serious treatment-related adverse events.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/phase-3-rapid-relief-thyroid-eye-disease-veligrotug-2026a1000ifw?src=rss |
| Publication time | Wed, 3 Jun 2026 02:54:48 EDT |
| Retrieval time | 2026-06-03T07:11:58.481Z |
| Last seen | 2026-06-03T07:11:58.481Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | -QL03O7GXB5T |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Veligrotug, a full antagonist monoclonal antibody targeting the insulin-like growth factor‑1 receptor, administered as five intravenous (IV) infusions over 12 weeks, demonstrated rapid and durable improvements in proptosis, diplopia, and disease activity in patients with moderate-to-severe active thyroid eye disease (TED). Most patients who had reduced proptosis at week 15 maintained that improvement through week 52. METHODOLOGY:Researchers conducted THRIVE, a global, multicenter, phase 3 trial across 29 sites in North America, Europe, and Australia to evaluate the efficacy and safety of veligrotug in patients with moderate-to-severe active TED.A total of 113 adult patients with moderate-to-severe active TED — with disease onset within 15 months, proptosis at least 3 mm above…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
